13 ОбзОРы лИтЕРАтуРы № 1/2010 О

№ 1/2010 ОстеОпОрОз и ОстеОпатии
ОбзОРы лИтЕРАтуРы
,
,
,
.
, . . .,
. . .
. . ., . . . . .
, . . .,
(
(
,
.
,
,
:
,
.
,
.
,
,
,
(
(
) [9].
,
0,5
34
— 0,4–18,8
.
) —
(
)
(
,
1000
10 000
)
,
55
—
2%,
2–3
[23,24].
,
,
(
.
,
2008
.
),
— 0,03
0,698
1000
,
2009
(.
,
5%.
,
, .
3%, 5%
,
,
[8].
(75%)
(80–85%),
—
(10%)
II
-1,
(20%),
(5%).
,
,
9%
-
1-5%)
-
,
:I
—
(
(
,
-
)
—
.
.
,
,
,
d
-
,
,
S-
2- d1,
,
)
,
44,0±4,0%,
,
-
.
.
,
(42±2,8
-
—
)
,
Prad1-
,
-
,
,
11q13,
— 11p15.
Prad1
.
—
Prad1,
[3].
,
(5%)
.
(
2
,
.
(4%),
1
.
-
600
100
.
. ( .1,2)
,
-
,
,
.
-
,
(
,
-
.
6,6%.
-
,
),
1
,
-
.
1%,
:
-
.
,
.
,
,
,
),
,
-
.
,
,
. .
,
,
,
. . .
. .
.
—
-
,
,
,
,
)—
.,
*,
,
.
-
,
.
,
. carling
)
[11, 12].
d,
-
.,
d
,
-
13
ОбзОРы лИтЕРАтуРы
№ 1/2010 ОстеОпОрОз и ОстеОпатии
1,25(
)2d3,
2008
0,698
100
-
.
.
.
-
.
120
100
.
80
60
-
1970-
40
,
20
0
,
.
,
,
.1.
(
2009
400
,
0,03
(
).
(
)
(
-
5-10
350
,
300
,
.
250
.
,
,
80%[9]. (
1.)
5
200
460
150
100
64
33%,
6%.
50
,
50
,
0
.2.
(
-
-
.
.
,
2009 .)
:
,
;
,
,
(
(
,
);
(
,
);
(
—
,
,
,
Qt,
). [4, 5]
,
,
-
,
,
,
,
,
,
.
,
);
,
-
.
.
1.
,
14
,
(
,
).
0,5
363
.)
,
.
-2,5Sd
,
1000
,
,
,
/
)
,
(
) —
-
№ 1/2010 ОстеОпОрОз и ОстеОпатии
ОбзОРы лИтЕРАтуРы
,
.
,
,
,
,
,
,
.
,
,
,
/
,
,
.
-
-
(
[20].
,
),
.
90 %
,
15-20% [8].
70%,
-2,5 Sd — 20% [6].
,
,
,
(
.
,
"
(
,
,
.
7,9%,
,
,
-
,
,
(
-
-
,
,
,
4,5
,
.
,
,
(
,
—
-
,
-
,
.
,
.
[1].
/
3,49–3,99
.
,
,
),
,
-
,
[5].
-
,
10
41
,
—
,
.
-
.
-
.
60%
.
,
,
6-21% [4].
—
,
.
.
-
(57,1%)[2].
-
[4].
",
65%
,
. Stefenelli
,
,
,
.
,
[17].
,
.
-
,
).
.
-
,
,
).
.
,
-
,
.
),
-
.
-
(
[6].
4,5%
-
,
,
.
30% ,
-
.
,
10–15%
,
—
-
[3].
,
.
,
7–12%
.
,
-
,
,
,
,
.
,
-
).
,
,
-
,
60% [1].
/
.
.
-
,
15
ОбзОРы лИтЕРАтуРы
№ 1/2010 ОстеОпОрОз и ОстеОпатии
[16].
,
.
.
.
,
,
. [2]
,
-
d
d—
-
.
,
,
.
-
-6
0,2–0,3
87% .
(
.
50
,
,
,
.
0,5
.
16
.
,
.
[10].
-
,
.
.
,
,
.
(
;
,
,
,
-
(
,
-
,
);
;
,
);
[7] .
-
;
;
;
;
,
;
;
,
,
,
.
-
-
,
-
,
.
.
,
,
,
-
.
,
,
.
-
.
,
-
,
.
,
)
,
-
.
2
,
,
-
[14].
25
-
75%,
(
(
80%),
,
.
-
34%
.
- )
-
-
,
/raNkl,
[22].
,
36
.
.
,
,
.
500
—
.
,
,
-6
30%).
.
I
. [14].
(
-
99m
90% [13] .
.
,
99%.
,
-
)
,
,
d,
,
(
-
d,
.
-
.
.
.
,
,
,
-
.
,
,
.
-
-
№ 1/2010 ОстеОпОрОз и ОстеОпатии
.
,
ОбзОРы лИтЕРАтуРы
12
,
[2].
-
10,9% ( <0,001),
16,5% ( =0,025),
,
0,25
.
2.
3.
/
50
-2,5Sd
4.
/
5.
,
.
50
.
,
95-98%
,
1-2%
.
,
.
.
,
.
,
-
.
,
,
.
,
3,5-3,7
/ ,
,
.
.
.
,
-
-
.
,
,
,
«
).
,
)
«
(1500-3000
»
d(
.
-
.
(
,
3-8%
[15, 18].
)
,
.
,
.
,
.
,
,
,
(120-180
,
.
(
50%)
).
(
[19].
/
,
,
-
,
-
)
.
-
[13].
[19, 21].
-
-
,
-
,
.
»,
. [15,
-
,
,
,
.
-
,
,
-
II
,
18, 20].
.
-
.
,
,
.
,
.
[8].
.
-
-
.
60
.
[6],
.
.
(
2
,
-
:
2%
)
.
2008 .,
[16],
,
.
.
-
12-
,
.
1.
,
-
8,7%
( <0,001),
9,3% ( <0,001),
,
-
.
-
(
,
)
,
.
,
,
,
17
ОбзОРы лИтЕРАтуРы
№ 1/2010 ОстеОпОрОз и ОстеОпатии
,
-
.
.
»
—
(
23
)
,
62%
10
,
,
«
.
-
,
.
-
-
[8].
-
.
,
.
,
-
,
,
-
.
.
SUMMARY
Primary hyperparathyroidism (PHPT) is a common endocrine disorder that affects bones, urinary tract, cardiovascular
system, gastrointestinal tract, and another organs and tissues.
The most cases of PHPT are mild forms and those patients have
nonspeciic symptoms, which require careful diagnostic considerations and choice of treatment.
There is not enough data about prevalence of PHPT, especially it’s mild forms, in Russian Federation, and future epidemiological research needs to be done.
Present literature review includes information about etiology, pathogenesis, clinical indings, diagnostic and differential
diagnostic, indication for surgery and medical treatment of
PHPT. The review is based on data of studies from the different
countries and few studies from Endocrine science center.
Key words. Primary hyperparathyroidism, epidemiology,
clinical indings, indications for surgery, medical treatment.
1.
2.
. .
medicum, 2006, 8(
. .
5.
6.
18
. .
9), .105—110.
. .
. . .
, 2005.
.
.
.
» // consilium
.«
.
2009 .
3.
4.
, . .
.
,
. .
. ,
. //
3- . 59. — .24—29.
. .«
. .,
,
-
//
. .
—
, . .
, 2006- 2, .33—41.
. .,
. .,
-
. / .. 2006 .
7. alok Sachdeva, Bruce e goeckeritz and alyce m oliver //
Symptomatic hypercalciemia in a patient with chronic tophaceous
gout: a case report // cases J. -2008 — 1 P.72.
8. the merican association of clinical endocrinologists and the
merican association of endocrine surgeons. Position statement on
the diagnosis and management of primary hyperparathyroidism.
endocrine practice vol 11 no. 1 January/february 2005.
9. Bilezician JP, Potts Jt Jr, fuleihan, gel-h et al. Summary
statement from a workshop on asymptomatic primary
hyperparathyroidism: a perspective for the 21-st century. J Bone
mineral res 2002 ; 17 Suppl 2:N2.
10. Brian h. eisner, m.d., Jennifer ahn, B.a., and marshall
l. Stoller, m.d. differentiating Primary from Secondary
hyperparathyroidism in Stone Patients: the «thiazide challenge»
journal of endourology vol. 23, number 2, february 2009.
11. carling ., rastad J., Szabo e. et al. reduced parathyroid vitamin
d receptor messenger ribonucleic acid levels in primary and
secondary hyperparathyroidism // J. clin. endocrinol. metab. —
2000.—vol. 85, — P. 2000—2003.
12. carling ., Szabo e., Bai m. et al. familial hypercalcemia and
hypercalciuria caused by a novel mutation in the cytoplasmic tail of
the calcium receptor // J. clin. endocrinol. metab. — 2000. —vol. 85,
P. 2042—2047.
13. P Iglesias, J J dıez. current treatments in the management of
patients with primary hyperparathyroidism. Postgrad. Med. J.
2009;85;15—23.
14. kaji1 h., r. Nomura1, m. yamauchi, k. chihara1, t. Sugimoto
the usefulness of Bone metabolic Indices for the Prediction
of changes in Bone mineral density after Parathyroidectomy
in Patients with Primary hyperparathyroidism // horm metab
res.—2006; 38(6): 411—6.
15. khan a, Bilezikian J, kung a et al. alendronate in Primary
hyperparathyroidism: a double-Blind, randomized, Placebocontrolled trial. J Clin.Endocrinol.Metab — 2004 — 89(7)
— pp.3319—25.
16. khan a.a., Bilezikian J.P., Potts J.t., Jr. the third International
Workshop on asymptomatic Primary hyperparathyroidism. // J
clin endokcrin metab, february 2009, 94(2):333—334.
17. kushner d. calcium and the kidney // the american Journal of
clinical Nutrition — 2006 vol. 4 N.5 — pp. 561—579.
18. Parker c., Blackwell P., fairbairn k., d. J. hosking. alendronate
in the treatment of Primary hyperparathyroid-related
osteoporosis: a 2-year Study. J Clin.Endocrinol.Metab — 2002
— 87(10) — pp.4482—9.
19. Peacock m, Bolognese ma, Borofsky m, Scumpia S, Sterling
Lr, cheng S, Shoback d. cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a ive-year study. J clin endocrinol metab. 2009
dec;94(12):4860-7. epub 2009 oct 16.
20. rossini m, gatti d, Isaia g, Sartori l, Braga v, adami S 2001
effects of oral alendronate in elderly patients with osteoporosis
and mild primary hyperparathyroidism. J Bone miner res
16:113—119.
21. Steddon S.J, cunningham J calcimimetics and calciuritic —
fooling the calcium receptor. // lancet 365:2237—2239, 2005.
22. Stilgren l.S., rettmer e., eriksen e.f., hegedus l., Beck-Nielsen
h., abrahamsen B. Skeletal changes in osteoprotegerin and
receptor activator of nuclear factor-kappab ligand mrNa levels
in primary hyperparathyroidism: effect of parathyroidectomy
and association with bone metabolism // Bone.-2004; 35(1):
256—65.
23. Ning yu*, Peter t. donnan*, michael J. murphy† and graham P.
leese. epidemiology of primary hyperparathyroidism in tayside,
Scotland, uk . clinical endocrinology (2009) 71, 485—493.
24. Wermers ra, khosla S, atkinson eJ et al. Incidence of primary
hyperparathyroidism in rochester, minnesota, 1993-2001: an
update on the changing epidemiology of the disease. // J Bone
miner res. 2006 Jan;21(1):171—7.
, 2009 —
. .
»
-
* – e-mail: [email protected]